Contents

About the Authors xi
Preface xiii
Acknowledgments xv

1. Chemical Basis of Lipid Biochemistry 1

1.1 Introduction 1
1.2 Chemistry Background 2
1.3 Molecular Interactions 3
1.4 Solubility in Water: What Is It? 4
1.5 Lipid Biochemistry 6
1.5.1 Definition 6
1.5.2 Biochemistry of Fatty Acids 7
1.5.3 Biochemistry of Saturated Fatty Acids 7
1.5.4 Biochemistry of Unsaturated Fatty Acids 9
1.5.5 Glycerolipids 11
1.5.6 Sphingolipids 14
1.5.7 Sterols 23
1.6 Biochemical Diversity of Brain Lipids 24
1.7 A Key Experiment: Lipid Analysis by Thin Layer Chromatography 25
References 26

2. Brain Membranes 29

2.1 Why Lipids are Different from all other Biomolecules 29
2.2 Role of Structured Water in Molecular Interactions 30
2.3 Lipid Self-assembly, a Water-Driven Process? 31
2.4 Lipid–Lipid Interactions: Why Such a High Specificity? 35
2.4.1 Melting Temperature of Lipids 36
2.4.2 The Molecular Shape of Lipids 38
2.5 Nonbilayer Phases and Lipid Dynamics 45
2.6 The Plasma Membrane of Glial Cells and Neurons: The Lipid Perspective 45
2.7 Key Experiments on Lipid Density 49
References 49

3. Lipid Metabolism and Oxidation in Neurons and Glial Cells 53

3.1 General Aspects of Lipid Metabolism 53
3.2 Cholesterol 56
3.3 Sphingolipids 61
3.3.1 Biosynthesis of Ceramide in the Endoplasmic Reticulum 62
3.3.2 Biosynthesis of Sphingomyelin in the Golgi 62
3.3.3 Glycosphingolipids 63
3.3.4 Sphingolipid Messengers 66
3.4 Phosphoinositides 70
3.5 Phosphatidic Acid 71
3.6 Endocannabinoids 74
3.7 Lipid Peroxidation 76
3.8 Key Experiment: Alzheimer's Disease, Cholesterol, and Statins: Where is the Link? 76
References 78

4. Variations of Brain Lipid Content 87

4.1 Brain Lipids: How to Bring Order to the Galaxy 87
4.2 Variations in Brain Cholesterol Content 89
4.2.1 Cholesterol and Aging 89
4.2.2 Brain Cholesterol and Neurodegenerative Diseases 92
4.3 Variations in Brain Ganglioside Content 93
4.3.1 Ceramide Variability 93
4.3.2 Sugar Head Group Variability 95

9.4 Role of Lipid Rafts in the Conformational Plasticity of PrP 208
9.5 Conclusion of the Investigation: Who is Guilty, Who is Innocent? 218
9.6 Key Experiment: Adenine is a Minimal Aromatic Compound that Self-aggregates in Water Through π–π Stacking Interactions 218
References 219

10. Parkinson's Disease 223

10.1 Parkinson's Disease and Synucleopathies 223
10.2 α-Synuclein 224
10.3 Intracellular α-Synuclein Binds to Synaptic Vesicles and Regulates Vesicle Trafficking, Docking, and Recycling 226
10.4 α-Synuclein is Secreted, Extracellular, and Taken up by Several Brain Cell Types 227
10.5 α-Synuclein: A Multifaceted Protein with Exceptional Conformational Plasticity 228
10.6 How α-Synuclein Interacts with Membrane Lipids 231
10.7 Oligomerization of α-Synuclein into Ca^{2+}-Permeable Annular Channels 236
10.8 Electrophysiological Studies of Oligomeric α-Synuclein Channels 239
10.9 Cellular Targets for α-Synuclein in the Brain: The Lipid Connection 241
10.10 Conclusion of the Investigation: Who is Guilty, Who is Innocent? 243
10.11 Key Experiment: Pesticides and Animal Models of Parkinson's Disease 244
References 245

11. Alzheimer's Disease 253

11.1 Alzheimer's Disease: a Rapid Survey, from 1906 to 2014 253
11.2 The Amyloid Paradigm 255
11.3 The Calcium Hypothesis of Alzheimer's Disease 257
11.4 Amyloid Pores: β, α, or Both? 258
11.5 Cholesterol 260
11.6 GM1 263
11.7 Lipid Rafts: Matrix for APP Processing and Factory for Aβ Production 266
11.8 Gender-specific Mechanisms 268
11.9 Conclusions of the Inquiry 270
11.10 Key Experiment: A Blood-Based Test to Predict Alzheimer's Disease? 271
References 271

12. Viral and Bacterial Diseases 279

12.1 Overview of Brain Pathogens 279
12.2 Pathogen Traffic to the Brain 280
12.2.1 Rabies Virus: A Traveler to the Brain via Retrograde Axonal Routes 280
12.2.2 HIV: Strategies for Crossing the Blood–Brain Barrier 285
12.2.3 Listeria Monocytogenes 289
12.3 Overview of Brain Pathogens 293
12.3.1 Bacteria 293
12.3.2 Viruses 297
12.4 Key Experiment: What is a Virus Receptor? 301
References 303

13. A Unifying Theory 313

13.1 Why do we Need a Unifying Theory? 313
13.2 Bacteria, Viruses, and Amyloids Converge at Brain Membranes 314
13.3 Glycosphingolipids and Cholesterol in Brain Membranes: "Un Pas De Deux" 315
13.4 Geometric Aspects of Glycolipid–Protein and Cholesterol Interactions 324
13.5 Why Two Lipid Receptors are Better Than One? 327
13.6 When Cholesterol Plays Two Roles 328
13.7 Structural Disorder as a Common Trait of Pathogenicity 329
13.8 Key Experiment: Probes to Study Cholesterol and/or Glycolipid-Dependent Mechanisms 330
References 332

14. Therapeutic Strategies for Neurodegenerative Diseases 337

14.1 Proteins Involved in Brain Diseases Considered as Infectious Proteins 337
14.2 How to Prevent the Interaction of Pathogenic Proteins with Brain Membranes 338

14.3 How to Prevent the Insertion of Pathogenic Proteins into Brain Membranes 340
14.4 How to Block Amyloid Pore Formation 340
14.5 A Universal Ganglioside-Binding Peptide 340
14.6 A Universal Squatter of Cholesterol-Binding Sites 346
14.7 Could Anti-HIV Drugs Also be Considered for the Treatment of Neurodegenerative Diseases? 355
14.8 Conclusions 357
14.9 A Key Experiment: PAMPA-BBB, a Lipid-Based Model for the Blood–Brain Barrier 357
References 359

Glossary 365
Subject Index 369